Welcome to Specialised Therapeutics

SE Asia
+65 3158 9940
1300 798 820
New Zealand
+64 9801 0299

Home
About
Products
Pipeline
Partnering
News and Resources
Orders
Contact us

Home
About
Products
Pipeline
Partnering
News and Resources
Orders
Contact us

Guidelines and Pivotal Trial Results for palopegteriparatide

Home
Yorvipath
Guidelines and Pivotal Trial Results for palopegteriparatide

Professor Aliya Khan discusses Guidelines and Pivotal Trial Results for palopegteriparatide

< Back to Previous Page

Share This Post

Categories

ST Patients Magazines

Recent News

Building from a Solid Foundation:...

February 15, 2024

Patient Experience – Small Cell...

November 2, 2023

Specialised Therapeutics Signs Exclusive License...

October 13, 2023

Keyword

Australia axatilimab breast cancer cGVHD cholangiocarcinoma Chronic GVHD distributor follicular lymphoma GIST graft-versus-host disease GVHD HER2+ HR+ Hypoparathyroidism leiomyosarcoma liposarcoma logistics lurbinectedin marinescience Minjuvi nerlynx New Zealand Niktimvo oncology pbs Pemigatinib pharma Philippines qinlock R/R FL refractory follicular lymphoma relapsed follicular lymphoma retifanlimab Sarcoma Singapore small cell lung cancer softtissuesarcoma Tafasitamab thailand trabectedin Yondelis Yorvipath Zepzelca Zynyz

For more information about this article, please send an email to:

E: communications@stbiopharma.com

With the highest professional and ethical standards, we commercialise therapies and technologies that uniquely fulfil the unmet needs of our community.

Quick Links

Home
About
Products
Pipeline
News & Resources
Orders
Contact us

Latest News

New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia

May 4, 2026

MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia

April 23, 2026

Follow Us

Privacy Policy | Terms and Conditions | Site Map | Copyright © 2021 Specialised Therapeutics